UPDATE CONCERNING COVID-19 (NOVEL CORONAVIRUS)

Due to the COVID-19 situation, the 21st International Conference on Alzheimer’s Drug Discovery will be hosted online.

This annual conference will showcase the innovative approaches of Alzheimer’s Drug Discovery Foundation’s (ADDF) funded scientists and their newest results. In addition to featuring ADDF’s portfolio, the program will also include guest presentations focusing on the latest research in the Alzheimer’s disease field.

The program features five sessions:

  1. Novel Approaches for Neuroinflammation
  2. Metabolic and Mitochondrial Approaches for Alzheimer’s Disease
  3. Emerging Areas in Drug Development for Neurodegeneration
  4. Neuroprotection, Synaptic Health and Neurotransmitters
  5. Novel Biomarkers in Alzheimer’s Disease

The registration for this conference will be free though a brief form available at the Registration page.

OBJECTIVES

  • Highlight scientific progress on drug development programs aimed at treating Alzheimer’s disease and related dementias.
  • Increase opportunities for early career investigators and start-up companies to share information and resources.
  • Foster interdisciplinary and public-private partnerships and alliances.
}

SHORT PRESENTATION DEADLINE

The deadline to submit an entry for the Virtual Poster or the Start-up Forum presentations is August 21, 2020.

CONFERENCE HIGHLIGHTS

22 Speakers

Virtual Poster Presentations

Start-up Forum

Virtual Q&A

Ample sponsorship opportunities

Complimentary Registration

FOCUS

The purpose for this annual ADDF conference is to accelerate the development of innovative treatments for Alzheimer’s disease, related dementias and cognitive aging.

Attendees will see the diverse cutting-edge approaches ADDF scientists are undertaking and have opportunities for networking and partnership discussions with academic, industry, and foundation thought leaders.

AUDIENCE

The 2019 edition of this conference attracted close to 130 attendees from around the world.  Attendees included:

  • Academic and industry scientists engaged in drug discovery research for neurodegenerative diseases and CNS
  • Business development and licensing professionals
  • Alliance management professionals
  • Venture capitalists and other investors
  • Graduate students, PhD candidates and post-doctoral fellows.

SPEAKERS AND CHAIRS

Darren Baker
Mayo Clinic

CJ Barnum
INmune Bio

Nicole Bjorklund
ADDF

Ronald Crystal
Weill Cornell MC

Paul Edison
ICL

Howard Fillit
ADDF

Hüseyin Firat
Amoneta

Lauren Friedman
ADDF

Douglas Galasko
UC San Diego

Gary Gibson
Burke Neuro. Inst

Mark Gurney
Tetra Therapeutics

Lampros Kourtis
Circadic

Chunlei Liu
UC Berkeley

Nick McKeehan
ADDF

Ralph Nixon
NS Kline Inst.

Meriel Owen
ADDF

Ana Pereira
ISMMS

Dianne Perez
CCF

Martin Pomper
Johns Hopkins U.

Amy Ripka
Lucy Tx

Sharon Rosenzweig-Lipson
AgeneBio

Edward Spack
Vector BioSol./Therini

Sidney Strickland
The Rockefeller Univ.

Alessio Travaglia
ADDF

Samuil Umansky
DiamiR Biosciences

Linda Van Eldik
Univ. of Kentucky

Henrik Zetterberg
Univ. of Gothenburg

Berislav Zlokovic
USC

Join us today!

Reserve a virtual seat at the conference, consider sponsoring the event,
submitting an application for a virtual poster or start-up presentation or simply, spread the word about it!